Investing

Corcept Therapeutics : CORT

CORT

Stock Data

$51.42

$4.90 (10.53%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Corcept Therapeutics Inc is a biopharmaceutical company based in Menlo Park, California, focusing on the development of drugs to treat severe disorders such as endocrinologic, oncologic, metabolic, and neurologic conditions. Its flagship product, Korlym, helps manage hyperglycemia caused by Cushing's syndrome. The company is also advancing a robust pipeline, including relacorilant for Cushing's syndrome and other candidates targeting adrenal cancer, prostate cancer, ovarian tumors, amyotrophic lateral sclerosis, nonalcoholic steatohepatitis, and antipsychotic-induced weight gain, with several treatments in late-stage clinical trials.

All Corcept Therapeutics Articles

1 Article

William Temple | Jan 15, 2026 at 6:47 AM EST

One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit

Corcept Therapeutics (NASDAQ: CORT) and Amicus Therapeutics (NASDAQ: FOLD | FOLD Price Prediction) delivered Q3 2025 results highlighting two rare…